Table 3.
Rates of secondary efficacy endpoints in the study (per‐protocol cohort)
| Endpoint, time period (hours) | NEPA + DEX1 (n = 76) | NEPA + DEX3 (n = 76) | NEPA + DEX4 (n = 76) | ||
|---|---|---|---|---|---|
| % of patients | RD, % (95% CIa) | % of patients | RD, % (95% CIa) | % of patients | |
| No emetic episodes | |||||
| Acute (0–24) | 96.1 | −2.6 (−7.7–2.4) | 96.1 | −2.6 (−7.7–2.4) | 98.7 |
| Delayed (>24–120) | 92.1 | −5.3 (−12.3–1.8) | 90.8 | −6.6 (−14.0–0.9) | 97.4 |
| Overall (0–120) | 92.1 | −5.3 (−12.3–1.8) | 90.8 | −6.6 (−14.0–0.9) | 97.4 |
| Complete protectionb | |||||
| Acute (0–24) | 90.8 | 1.3 (−8.2–10.8) | 80.3 | −9.2 (−20.5–2.1) | 89.5 |
| Delayed (>24–120) | 73.7 | 6.6 (−7.9–21.1) | 67.1 | 0 (−14.9–14.9) | 67.1 |
| Overall (0–120) | 73.7 | 6.6 (−7.9–21.1) | 67.1 | 0 (−14.9–14.9) | 67.1 |
| No nausea | |||||
| Acute (0–24) | 73.7 | −10.5 (−23.4–2.3) | 68.4 | −15.8 (−29.1 to −2.5c) | 84.2 |
| Delayed (>24–120) | 50.0 | −10.5 (−26.2–5.2) | 48.7 | −11.8 (−27.6–3.9) | 60.5 |
| Overall (0–120) | 48.7 | −11.8 (−27.6–3.9) | 46.1 | −14.5 (−30.2–1.2) | 60.5 |
| No significant nausea | |||||
| Acute (0–24) | 93.4 | −3.9 (−10.6–2.7) | 86.8 | −10.5 (−18.9 to −2.1c) | 97.3 |
| Delayed (>24–120) | 77.6 | 1.3 (−12.1–14.7) | 73.7 | −2.6 (−16.4–11.1) | 76.3 |
| Overall (0–120) | 77.6 | 1.3 (−12.1–14.7) | 73.7 | −2.6 (−16.4–11.1) | 76.3 |
| No rescue use | |||||
| Acute (0–24) | 97.4 | 6.6 (−0.9–14.0) | 92.1 | 1.3 (−7.6–10.2) | 90.8 |
| Delayed (>24–120) | 78.9 | 3.9 (−9.4–17.3) | 80.3 | 5.3 (−8.0–18.5) | 75.0 |
| Overall (0–120) | 78.9 | 3.9 (−9.4–17.3) | 80.3 | 5.3 (−8.0–18.5) | 75.0 |
a
The 95% confidence interval for the risk difference between the DEX1 or DEX3 groups and the DEX4 group.
b
Complete protection defined as no emetic episodes, no use of rescue medication, and no more than mild nausea.
c
Two‐sided p value < .05 in a post hoc superiority contrast.
Abbreviations: CI, confidence interval; DEX1, dexamethasone day 1; DEX3, dexamethasone day 1 to 3; DEX4, dexamethasone day 1 to 4; NEPA, fixed‐dose combination of netupitant and palonosetron; RD, risk difference.